Breaking News

Q BioMed, Bio-Nucleonics Submit New Facility Filing

After approval, the facility will be permitted to manufacture Strontium Chloride Sr89 Injection USP

Q BioMed Inc. and Bio-Nucleonics, the licensor of Strontium 89 Chloride, have submitted a regulatory filing to the FDA for the approval of a new manufacturing facility. Upon approval by the FDA, the facility will be permitted to manufacture Strontium Chloride Sr89 Injection USP (Strontium-89) in accordance with cGMP.    Strontium-89 is a non-opioid injectable radiopharmaceutical to relieve cancer bone pain in patients with painful skeletal metastases. In the body, strontium acts similar ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters